

## **Fear expression is suppressed by tyrosine administration**

SORANZO, Alessandro <<http://orcid.org/0000-0002-4445-1968>> and AQUILI, Luca <<http://orcid.org/0000-0003-4930-1536>>

Available from Sheffield Hallam University Research Archive (SHURA) at:

<http://shura.shu.ac.uk/25314/>

---

This document is the author deposited version. You are advised to consult the publisher's version if you wish to cite from it.

### **Published version**

SORANZO, Alessandro and AQUILI, Luca (2019). Fear expression is suppressed by tyrosine administration. *Scientific Reports*, 9 (1), p. 16073.

---

### **Copyright and re-use policy**

See <http://shura.shu.ac.uk/information.html>

OPEN

# Fear expression is suppressed by tyrosine administration

Alessandro Soranzo &amp; Luca Aquili\*

Animal studies have demonstrated that catecholamines regulate several aspects of fear conditioning. In humans, however, pharmacological manipulations of the catecholaminergic system have been scarce, and their primary focus has been to interfering with catecholaminergic activity *after* fear acquisition or expression had taken place, using L-Dopa, primarily, as catecholaminergic precursor. Here, we sought to determine if putative increases in presynaptic dopamine and norepinephrine by tyrosine administered *before* conditioning could affect fear expression. Electrodermal activity (EDA) of 46 healthy participants (24 placebo, 22 tyrosine) was measured in an instructed fear task. Results showed that tyrosine abolished fear expression compared to placebo. Importantly, tyrosine did not affect EDA responses to the aversive stimulus (UCS) or alter participants' mood. Therefore, the effect of tyrosine on fear expression cannot be attributed to these factors. Taken together, these findings provide evidence that the catecholaminergic system influences fear expression in humans.

Pavlovian fear conditioning is a valuable behavioural paradigm suitable for neurobiological and physiological analyses<sup>1</sup> in both animals and humans. Typical fear conditioning protocols in animals consist of presenting a conditioned stimulus (CS) followed by an aversive stimulus (UCS), in a process described as fear *acquisition*. In humans, fear conditioning protocols can also be “instructed” where explicit instructions about CS-UCS contingencies are provided prior to testing. To distinguish between uninstructed and instructed protocols, some authors have suggested to refer to the former as measuring fear *acquisition* and to the latter as fear *expression*<sup>2</sup>, in that learning can already take place in the instruction phase. In the animal literature, however, the term *fear expression* is used to describe conditioned responses (CR) that have developed *following* fear acquisition when the CS is presented in the absence of the UCS.

Using the Pavlovian paradigm, a growing body of literature has indicated the catecholaminergic system as playing a significant role in the acquisition, expression and extinction of fear responses. Animal studies have demonstrated the involvement of dopaminergic D1, D2, D3 and D4 receptors in the amygdala in fear conditioning. D1 and D2 antagonists block the acquisition of fear memories<sup>3–7</sup> whilst the administration of D1 or D2 agonists increase fear expression<sup>8,9</sup>. Blockade of D3 receptors has, surprisingly, shown to enhance fear acquisition<sup>10</sup>, whilst D4 activation potentiates acquisition<sup>11</sup>. In humans, the effects of a dopamine reuptake blocker (Ritalin) or a dopamine precursor (L-Dopa) have only been investigated with respect to fear extinction and spontaneous recovery<sup>12,13</sup>, but not fear acquisition.

Animal studies have also revealed an important role of norepinephrine (NE) in fear conditioning (for an extensive review, please see<sup>14</sup>). Administration of the non-selective  $\beta$ -adrenergic receptor antagonist propranolol prior to training impairs fear acquisition<sup>15,16</sup>. Similarly, administration of the selective  $\alpha$ 2-adrenergic agonist dexmedetomidine (which decreases activity of NE neurons), weakened cued conditioning<sup>17</sup>. Genetic studies in which NE was reduced, enhanced, or eliminated as in knockout investigations have revealed a more complex picture with respect to the role of NE in fear acquisition<sup>16–18</sup>.

Overall, despite some complex interaction effects, there is robust evidence to suggest that dopamine and norepinephrine are involved in the acquisition/expression of fear responses.

In humans, investigations of dopamine and norepinephrine have been scarce, and have largely focused on the study of extinction, extinction consolidation and reconsolidation processes<sup>19–28</sup>, or in those with posttraumatic stress disorder<sup>29,30</sup>. In these studies, catecholaminergic activity was manipulated *after* fear conditioning had taken place. However, given the existing animal literature, catecholaminergic activity may also be important in regulating fear acquisition and/or expression. To understand whether fear expression is affected, one would need to manipulate dopamine and norepinephrine tone *before* conditioning. Moreover, previous studies were limited to testing the effects of L-Dopa as a catecholaminergic precursor.

Department of Psychology, Sociology and Politics, Sheffield Hallam University, Sheffield, UK. \*email: [luca.aquili@shu.ac.uk](mailto:luca.aquili@shu.ac.uk)

In this research, we set out to answer: (i) whether alterations in catecholaminergic tone *before* conditioning would affect fear expression and (ii) whether a different catecholaminergic precursor to L-Dopa namely tyrosine would modulate this effect.

There are good theoretical reasons for the use of tyrosine rather than L-Dopa. The conversion mechanism of tyrosine to dopamine and norepinephrine is restricted to by competition from other endogenous amino acids and by the rate-limiting tyrosine-hydroxylase enzyme whilst L-Dopa is not<sup>31</sup>. As a result, these restrictions would limit the overall enhancement in dopamine and norepinephrine levels from tyrosine. This is important given that low or high doses of drugs that alter dopamine and norepinephrine levels enhance or impair fear conditioning respectively<sup>32,33</sup>.

Here, in a randomized, double-blind study, we tested the effects of tyrosine (placebo controlled) administered *before* fear conditioning. To test the experimental hypothesis that administration of tyrosine would enhance fear expression, skin conductance responses (SCR) were measured in 46 healthy volunteers while undertaking a fear conditioning task.

## Results

**SCR magnitudes in fear expression.** Skin conductance responses (SCR) have been used to measure the effects of tyrosine and of placebo (cellulose) administration in a fear conditioning task. Drug administration occurred 60 minutes before fear conditioning. The task had a fear expression phase during which a conditioned stimulus (CS+) predicted the occurrence of an unconditioned stimulus (UCS: 75 db loud beep played through a pair of earphones) whereas another conditioned stimulus predicted the occurrence of a neutral event (CS–, which was a fixation dot, Fig. 3A). CS+ and CS– were paired six times. Responses were analysed on a trial by trial basis.

A  $2 \times 2 \times 6$  factorial mixed analysis of variance was conducted on SCR magnitudes during the fear expression phase. The between group variable, *drugs*, having two levels (placebo, tyrosine) the first within subject variable, *stimulus*, having two levels (CS+, CS–), and the second within subject variable, *trial*, having six levels (trial 1–6). There was neither a significant main effect of drugs,  $F(1, 44) = 0.721, p = 0.400, \eta^2 = 0.016$ , nor a main effect of stimuli,  $F(1, 44) = 1.678, p = 0.202, \eta^2 = 0.037$ , nor a trial  $\times$  drugs,  $F(5, 44) = 1.781, p = 0.118, \eta^2 = 0.039$ , nor a trial  $\times$  drugs  $\times$  stimuli significant interaction,  $F(5, 44) = 0.664, p = 0.651, \eta^2 = 0.015$ .

There was, however, a significant main effect of trial,  $F(1, 44) = 9.342, p < 0.001, \eta^2 = 0.175$ , a significant trial  $\times$  stimulus interaction,  $F(3.8, 167) = 3.719, p = 0.017, \eta^2 = 0.067$ , and most importantly, a significant drugs  $\times$  stimuli significant interaction,  $F(5, 44) = 4.306, p = 0.044, \eta^2 = 0.089$  (see Fig. 1A).

To break down this significant interaction, planned comparisons demonstrated that in the placebo group, there were significantly higher SCRs for CS+ than CS–,  $t(23) = 3.612, p = 0.001, d = 0.73$ , however this was not the case in the tyrosine group,  $t(23) = 0.427, p = 0.674, d = 0.13$ . When comparing SCRs for CS+ between the placebo and tyrosine group, significantly higher fear responses occurred for the placebo than tyrosine group,  $t(44) = 2.914, p = 0.006, d = 0.92$ , whilst no significant differences were reported for CS–,  $t(44) = 0.470, p = 0.641, d = 0.13$  (see Fig. 1B). These findings therefore demonstrate that tyrosine impairs fear expression.

**Control measures: SCR magnitudes during UCS.** We checked whether tyrosine effects on fear conditioning could be ascribed to an association between CS+ and UCS, as opposed to unspecific systemic effects on UCS alone. We therefore conducted a drugs  $\times$  time mixed ANOVA of the responses to the UCS.

There was a significant main effect of time ( $F(1, 44) = 16.89, p < 0.001, \eta^2 = 0.277$ ). This indicates that SCRs to UCS decreased over time regardless of the drug (see Fig. 2A). Importantly, there was neither a main effect of drugs ( $F(1, 44) = 0.001, p = 0.985, \eta^2 = 0.000$ ) nor a time  $\times$  drugs significant interaction ( $F(1, 44) = 0.632, p = 0.431, \eta^2 = 0.014$ ).

**Control measures: mood, double blinding efficacy and fear ratings.** Transient changes in mood state have been demonstrated to influence fear learning expression<sup>34</sup>. We therefore administered a visual analogue scale (VAS) questionnaire before and after drug administration (but before fear conditioning: see Fig. 3B). We also checked whether the double blinding procedure of tyrosine/placebo administration had been effective.


There was neither a significant main effect of drugs on mood scores ( $F(1, 44) = 0.004, p = 0.951$ ) nor a drugs  $\times$  time interaction on mood scores ( $F(1, 44) = 1.54, p = 0.220$ ). The probability of participants guessing the correct drug (placebo or tyrosine) was below chance at 39% (42% for placebo and 36% for tyrosine).

In a separate control experiment, fear/valence ratings to CSs (CS+ and CS–) were evaluated using an additional computerized VAS with values ranging from 0 (no fear/stress/tension) to 100 (maximal fear/stress/tension) (see Procedures), as per administered by Haaker *et al.*<sup>35</sup>.


There was neither a significant main effect of block on VAS fear ratings ( $F(1, 17) = 3.73, p = 0.070$ ), nor a block  $\times$  stimuli significant interaction ( $F(1, 17) = 1.332, p = 0.264$ ). Importantly, there was a significant main effect of stimuli ( $F(1, 17) = 417.4, p < 0.001$ ), demonstrating robust conditioning effects to the CS+ (Fig. 2B).

In a second control experiment, participants ( $N = 21$ ) were asked to rate the perceived aversiveness of the UCS based on three dimensions, *unpleasantness*, *intensity*, and how *startled they were* (see Procedures), as per previously published protocols<sup>36</sup>. Participants rated the UCS as *unpleasant* ( $M = 76.2, SD = 6.1$ ), *intense* ( $M = 68.4, SD = 6.6$ ), and were *moderately to strongly startled* ( $M = 74.2, SD = 8.2$ ), demonstrating the overall perceived aversiveness of the UCS (Fig. S1).

**SCR magnitudes in extinction.** As tyrosine blocked fear expression, we cannot interpret its effects in extinction and we report these results only for completeness in the supplementary file, together with its Figure. (S2).



**Figure 1.** (A) Line chart representing skin conductance responses measured in magnitudes across trials (1–6), based on SCR responses to CS+ and CS– in the placebo and tyrosine groups during the fear expression phase. (B) Bar chart highlighting the stimuli  $\times$  drugs significant interaction. Vertical lines represent standard error of the mean. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p = 0.001$ .



**Figure 2.** (A) Line chart representing skin conductance responses to UCS measured in magnitudes during early and late trials in the placebo and tyrosine groups. (B) Fear ratings to CS+/CS– measured using a Visual Analogue Scale during expression in a second experiment.

## Discussion

Numerous studies over the last decade have demonstrated an involvement of dopamine and norepinephrine in both fear acquisition, expression and extinction. Most of these investigations have been carried out in rodents. In humans, work has been limited to manipulations of catecholaminergic activity post fear acquisition learning and hence focusing on extinction, extinction consolidation and reconsolidation processes only.

This work provides novel evidence that a catecholaminergic precursor administered before conditioning abolishes fear expression. Specifically, augmentation of putative dopamine and norepinephrine levels by tyrosine administration rendered SCR responses to CSs in expression indistinguishable from one another (i.e. SCRs magnitudes to CS+ and CS– were approximately equal and cancelled each other out: see Fig. 1A,B). Moreover, SCRs to CS+ were greater in the placebo group than in those administered tyrosine. Importantly, tyrosine administration did not alter processing of UCS information (see Fig. 2A) demonstrating that tyrosine selectively weakened CS+ UCS associations. Moreover, there were no unspecific systemic changes of tyrosine administration on measures of mood and alertness, which may have affected fear expression.

It is worthwhile discussing the learning curve observed in the fear instructed paradigm. As can be seen in Fig. 1, fear responses to CSs decreased over time. Although this pattern is common in human studies<sup>20,37–39</sup>, it is the opposite in animals' studies<sup>4,8</sup>, in which fear responses increase over time.

There are a number of potential factors that can account for this phenomenon. These factors include the type of CS used, UCS identity and intensity, the length of inter-trial and inter-stimulus interval, the reinforcement rate, the trial number and order, the CS/UCS duration, the type of instructions (e.g. explicit CS-UCS contingency or not), whether the UCS was experienced prior to testing (i.e. UCS calibration), and variations in acquisition procedures (e.g. single-cue vs differential protocols; multiple-cue protocols) (for a more thorough review, see<sup>23</sup>).

Our findings that tyrosine abolished fear expression are important and surprising given that in the animal literature, increased fear acquisition and expression has been reported when a dopaminergic D1 agonist was administered<sup>8,9</sup> or abolished when D1/D2 receptors were blocked<sup>3–6</sup>. Similar results have been reported with respect to manipulations of norepinephrine<sup>14–17</sup>. These contrasting findings may partially be explained by methodological differences in manipulating dopaminergic and norepinephrine activity postsynaptically in animal studies and presynaptically in the current study. It is also plausible, though speculative at present that tyrosine administration may have interfered with the process of prediction error signalling. The strength of this signal would have been greatest in early trials, when the occurrence of the UCS is most surprising<sup>40</sup> and learning (of the CS-UCS pairing) is most likely to occur<sup>41,42</sup>. Midbrain dopaminergic neurons have long been known to convey a prediction error signal for rewards<sup>43,44</sup>, but more recent evidence also demonstrate a role for aversive events<sup>45–47</sup>. Nevertheless, because we employed an instructed fear conditioning protocol, the UCS presentation in the early trials should not have been very surprising, given that participants had been made aware of what to expect. Therefore, it is perhaps more plausible to suggest that differences between the animal literature and our current finding, relate to the use of an instructed fear paradigm. Previous research, in humans, has suggested that uninstructed fear conditioning paradigms (as in most animal studies) recruit a differential neuronal circuitry to that of instructed fear studies<sup>48</sup>.

With respect to human studies, our findings cannot directly be compared to previous investigations, especially those that manipulated dopaminergic activity *after* fear acquisition had taken place and investigated extinction and extinction consolidation. Onur *et al.* manipulated norepinephrine levels *before* conditioning. In their study, administration of the NE reuptake inhibitor reboxetine induced an amygdala response bias towards fear signals<sup>49</sup>. Similarly, Visser *et al.* reported a rise in salivary-amylase levels (a marker of markers of noradrenergic activation) prior to fear conditioning which correlated with fear consolidation expression<sup>50</sup>. Taken together, in humans, increasing catecholamines (using tyrosine) before fear conditioning impairs fear expression whilst pharmacological augmentation of norepinephrine before conditioning enhance fear acquisition. In animals, targeted manipulations of both dopamine and norepinephrine that either increase or decrease their release before fear conditioning enhance and impair acquisition learning respectively.

The choice of administering tyrosine instead of L-Dopa as in past studies was motivated by a number of reasons. Firstly, conversion of tyrosine into dopamine (and other catecholamines) is restricted by the transporter shared with other amino acids and by the rate-limiting TH enzyme. L-Dopa, on the contrary, is not affected by these and its administration would result in greater concentrations being converted to catecholamines<sup>31</sup>. However, given the well-established inverted U relationship between dopamine concentration and performance<sup>51</sup>, it is foreseeable that L-Dopa would be more likely than tyrosine to shift participants at the right end of the curve. This would be particularly the case in individuals who are homozygous for the Met/Met allele on the Val(108/158)Met COMT polymorphism, and possess higher baseline dopaminergic activity<sup>52</sup>. Secondly, an additional advantage of administering tyrosine is that it produces fewer and less severe side effects than L-Dopa (e.g. nausea, insomnia, psychosis)<sup>53</sup>.

As tyrosine is the precursor for dopamine, norepinephrine (noradrenaline) and epinephrine it can be concluded that these neurotransmitters are involved in fear expression. Finally, it is worth considering the implications of our data in the context of the pathogenesis of anxiety disorders. Two large meta-analyses<sup>54,55</sup>, looked at fear conditioned responses of healthy and anxiety patients to CS+, CS– and the conditioned response (CR) difference between (CS+) - (CS–). Contrary to theories by Davies and colleagues<sup>56</sup>, who suggested that healthy individuals would produce higher CRs to (CS+) than (CS–) compared to anxious individuals in acquisition, the data from the meta-analyses demonstrated that this was not the case. Similarly, the meta-analyses found no significant differences in responding to CS+ between healthy and anxious patients. Importantly, it was found that responding to the conditioned safety cue (CS–) was higher in anxious patients compared to healthy controls. These results suggest that any pharmacological agent with anxiolytic properties should reduce conditioned responses to CS– in anxious patients to match those of controls, and that in healthy participants the pharmacological agent would reduce even further conditioned responses to the safety cue compared to a placebo group.

Based on our data, we conclude that tyrosine did not have such anxiolytic properties, but rather, that impaired fear expression responses.

**Limitations and future directions.** Although we established that catecholamines contributed to fear expression, our study did not set out to reveal the neuronal pathways that would have determined this effect. Therefore, future investigations using imaging techniques (e.g. PET) would be required to understand how changes in dopamine/norepinephrine in brain regions of interest regulate fear expression (e.g. amygdala-prefrontal cortex). Furthermore, to obtain greater specificity with respect to dopamine for example, one would need to co-administer a noradrenergic blocker such as Clonidine together with tyrosine/L-Dopa, or target D1/D2 receptors. More crudely, reducing catecholaminergic neurotransmission using the acute phenylalanyl-tyrosine procedure<sup>57</sup> before conditioning, would provide a potential counter test for the effects of manipulating catecholamines on fear expression.

In conclusion, our results provide evidence that manipulating catecholaminergic tone before conditioning in humans can suppress fear expression.

## Method

**Participants.** Participants consisted of 46 university students ( $M = 20.4$ ,  $SD = 1.7$ ; 25 females and 21 males). The study was approved by the ethics committee of Sheffield Hallam University (SHU) and complied with the Declaration of Helsinki. All study methods were performed in accordance with SHU guidelines. Informed consent was obtained for all participants before testing could take place. Exclusion criteria included: those suffering from cardiac, hepatic, renal and neurological disorders and individuals with a history of alcohol or drug addiction, or psychiatric illness. Individuals having a history of taking tyrosine supplements were also excluded.

**Drug administration.** Participants received either 2.0 g of L-Tyrosine (supplied by BulkPowders Ltd.) or 2.0 g of the placebo microcrystalline cellulose (Redwells Creative Limited, UK) dissolved in 400 ml of orange juice as per previously published protocols<sup>58,59</sup>. Dosages greater than 2.0 grams have been shown not to provide additional benefits given that the rate-limiting tyrosine hydroxylase (TH) enzyme is already close to saturation under normal circumstances<sup>60</sup>. Peak plasma tyrosine levels have been reported to occur between 60 and 120 minutes post-ingestion<sup>61</sup>. In rats, increases in prefrontal dopamine concentrations can be observed 60 minutes following tyrosine administration<sup>62</sup>.

**Electrodermal activity recording.** Physiological recording were obtained using a BIOPAC MP150 data acquisition unit (Biopac Systems Inc., Santa Barbara, CA), and AcqKnowledge 4.4 software. Electrodermal activity (EDA) data were collected at 2000 samples/sec. Two disposable latex-free electrodes (EL507, BIOPAC) containing isotonic gel were attached to the distal phalanges of the index and middle fingers of the non-dominant hand. The EDA signal was then enhanced by a wireless BioNomadix<sup>®</sup> amplifier. Skin conductance responses (SCR) threshold was set at 0.01 microSiemens ( $\mu S$ ) with SCR onsets and peaks (i.e. a measure of change in tonic EDA) counted as being event related if occurring between 1–4.5 seconds following stimulus (CS+/CS–/UCS) onset. Data transformation of SCR magnitudes was applied using the square root ( $\sqrt{SCR}$ ) as in previously published protocols<sup>63</sup>. Participants who did not produce a measurable conditioned response (i.e. classified as CS+ = SCR amplitude not reaching the 0.01 threshold across the whole conditioning session) (8/56), a similar criterion to previous reports<sup>64</sup>, were discarded from the analyses as those with poor electrode contact/motion artefacts (2/56), giving us a remaining sample of 46 volunteers. Of those 46, 24 participants were in the placebo condition and 22 in the tyrosine. To confirm that the overall results were not dependent on the exclusion of these participants, we rerun these analyses excluding only those due to poor recording (2/56) and those who did not respond to the UCS (2/56) (i.e. not the outcome measure), giving us a remaining sample of 52 volunteers, 26 placebo and 26 tyrosine. These data (see Supplementary info) confirm the conclusions reached in the results section.


**Fear instructed task.** The conditioning task was programmed in OpenSesame<sup>65</sup>. Visual stimuli consisted of blue and yellow circles either predicting an aversive stimulus (CS+) or a neutral fixation dot (CS–). These were presented in a counterbalanced (i.e. half of the participants had the blue circle as CS+ and the other half had the yellow circle as the CS+) and randomized order (i.e. the CS+/CS– sequence varied for each participant). Before testing began, on screen instructions told participants which of the two CSs would be paired with the aversive stimulus (UCS) (as in “In this experiment, the following stimulus [image 1 shown] will be followed by a loud beep, whilst another stimulus [image 2 shown] will be followed by a neutral fixation dot [image 3 shown]. You are not required to perform any actions but to remain as still as possible throughout the duration of the experiment. The experiment will last approximately 8 minutes”) which consisted of a loud beep (75 db measured using an audiometer) lasting 1000 ms delivered through headphones. Moreover, participants were not exposed to the UCS prior to testing. In a previous pilot study, the UCS reliably elicited SCRs in over 90% of the trials.

The task was divided into an expression and an extinction phase. Each CS presentation lasted 5000 ms with an intertrial interval (ITI) of 10000 ms consisting of a fixation dot. During expression, there were 6 pairings of CS+ and UCS (as in CS+ for 5000 ms, followed by UCS for 1000 ms and fixation dot [ITI] for 10000 ms) and 6 of CS– (as in CS– for 5000 ms, followed by the same fixation dot for 10000 ms). The duration of the ITI was chosen based on previous reports<sup>19</sup> and permitted recovery of the SCR. In the extinction phase, both stimuli were unpaired (CS+ and CS– followed by the fixation dot) and presented 8 times each. The task lasted approximately 8 minutes. A schematic illustration of the task is shown in Fig. 3A.

**Control measures: mood, double-blinding efficacy and fear ratings.** We checked for the potential mood effects induced by tyrosine intake by administering a computerized adaptation of the visual analog scale (VAS) which was programmed and run in PEBL<sup>66</sup>, and has previously been used by our research group<sup>67–69</sup>. The scale consists of seven dimensions (e.g. boredom, sadness, relaxation, happiness, stress, alertness, calmness) of mood/alertness. The double-blinding efficacy of placebo/tyrosine administration was checked by a questionnaire (i.e. “Please circle whether you think you received a tyrosine containing drink (experimental) or a placebo, non-tyrosine containing drink (control)”) given to participants at the end of the experiment.

Fear ratings for CS+/CS– were measured in a separate cohort of participants ( $n = 18$ ) using a computerized VAS as per previous research groups<sup>35</sup>. Briefly, after the 3<sup>rd</sup> CS+/CS– pairing, and at the end of the last trial (trials 6 for both CS+ and CS–), participants rated each CS on a scale ranging from 0 (no fear/stress/tension) to 100 (maximal fear/stress/tension).

Additionally, we measured in a third cohort of participants ( $n = 21$ ) their perceived aversiveness to UCS presentation using a similar approach to that of Hermans *et al.*<sup>36</sup>. Note that, as reviewed elsewhere<sup>2</sup>, there is no agreed consensus on the precise procedural approach to measuring aversiveness (i.e. the type of visual/verbal scale used) and which criterion constitutes the threshold for the UCS being perceived as aversive, with minimum (aversiveness) scores ranging from 5 out of 10 to 8 out of 10. Using a computerized VAS, participants rated the UCS for



**Figure 3.** (A) Schematic representation of fear conditioning task. Stimuli were presented in a pseudorandomized order. In brackets (x6 or x8) indicate the number of CS+ or CS− pairings during expression and extinction. Time is shown in seconds. (B) Summary of experimental procedure. Q = questionnaire to assess the double-blind efficacy of placebo/tyrosine administration. VAS = visual analogue scale. T1 = time 1. T2 = time 2. Time is shown in minutes.

three characteristics; the first was the *unpleasantness* of the stimulus, with a score of 0 being described as *pleasant*, 50 *neutral*, and 100 *unpleasant*. The second was the *intensity* of the UCS, with 0 being classified as *light*, 50 *intense* and 100 *intolerable*. The third was how *startled* participants responded to the UCS, with 0 being labelled *not at all*, 50 *moderately*, and 100 *very strongly*. Participants were presented with the UCS six times, using similar timing intervals between each UCS as in the fear instructed study, but without CS+/CS−. After the last UCS, participants completed the VAS.

**Procedure.** This was a double-blind, placebo-controlled, mixed design experiment. Participants were required to attend a session lasting approximately 75 minutes. After screening for eligibility, participants were instructed to refrain from eating/drinking for a minimum of 3 hours. This is to reduce competition from other amino acids that share the same transporter<sup>70</sup>. They first signed a consent form followed by the mood questionnaire (VAS; time 1), and were then randomly assigned to receive either tyrosine or placebo. Participants were then asked to rest for 50 minutes following tyrosine/placebo intake, at the end of which, EDA electrodes were attached to the participant's index and middle finger. At 59 minutes (post tyrosine/placebo consumption), the VAS was completed for a second time (time 2). At 60 minutes, fear conditioning and EDA recording began. Participants were instructed to remain as still as possible during testing to reduce motion artefacts. Following this, participants completed the tyrosine/placebo double-blind questionnaire, and were debriefed (see Fig. 3B).

**Statistical analyses.** Sample size was estimated using the following parameters: power 0.8, alpha 0.05, mixed design ANOVA containing 2 groups, 2 repeated measurements and a large  $f^2$  effect size of 0.4 (G\*Power 3.1.9.2, Germany). The size of the effect size was based on the results of previous reports which looked at fear conditioning responses (SCR) using another catecholaminergic precursor (l-DOPA)<sup>20</sup>.

We performed a number of analyses on SCR measurements. First, we calculated expression responses on trial by trial basis (i.e. across the 6 CS+ and CS− pairings). The following variables were considered: Drugs (placebo and tyrosine), Trials (trial 1 to trial 6) and CS identity/stimuli (CS+, CS−). SCRs were measured 1–4.5 seconds following stimulus onset (CS+/CS−) which terminated after 5 second and hence did not include the UCS (which was presented between 5–6 seconds following CS+ onset), as in previous reports<sup>22,64</sup>, to isolate acquisition effects specific to the CS+ and not confounded by the UCS.

Second, we run a Drug (placebo and tyrosine) × Time (early trials, and late trials) ANOVA of the responses to the UCS, here also measuring SCRs to UCS in the 1–4.5 seconds following stimulus (UCS) onset. This type of analysis has been done by other research groups<sup>71</sup>, and allows to capture UCS encoding in acquisition.

Received: 1 March 2019; Accepted: 21 October 2019;

Published online: 05 November 2019

## References

- Johansen, J. P., Cain, C. K., Ostroff, L. E. & LeDoux, J. E. Molecular mechanisms of fear learning and memory. *Cell* **147**, 509–524 (2011).
- Lonsdorf, T. B. *et al.* Don't fear 'fear conditioning': Methodological considerations for the design and analysis of studies on human fear acquisition, extinction, and return of fear. *Neuroscience & Biobehavioral Reviews* **77**, 247–285 (2017).
- de Souza Caetano, K. A., de Oliveira, A. R. & Brandao, M. L. Dopamine D2 receptors modulate the expression of contextual conditioned fear: role of the ventral tegmental area and the basolateral amygdala. *Behavioural pharmacology* **24**, 264–274 (2013).

4. Guarraci, F. A., Frohardt, R. J., Falls, W. A. & Kapp, B. S. The effects of intra-amygdaloid infusions of a D<sub>2</sub> dopamine receptor antagonist on Pavlovian fear conditioning. *Behavioral neuroscience* **114**, 647 (2000).
5. Heath, F. C. *et al.* Dopamine D1-like receptor signalling in the hippocampus and amygdala modulates the acquisition of contextual fear conditioning. *Psychopharmacology* **232**, 2619–2629 (2015).
6. Nader, K. & LeDoux, J. Inhibition of the mesoamygdala dopaminergic pathway impairs the retrieval of conditioned fear associations. *Behavioral neuroscience* **113**, 891 (1999).
7. Stubbendorff, C., Hale, E., Cassaday, H. J., Bast, T. & Stevenson, C. W. Dopamine D1-like receptors in the dorsomedial prefrontal cortex regulate contextual fear conditioning. *Psychopharmacology*, 1–12 (2019).
8. Guarraci, F. A., Frohardt, R. J. & Kapp, B. S. Amygdaloid D1 dopamine receptor involvement in Pavlovian fear conditioning. *Brain research* **827**, 28–40 (1999).
9. Nasehi, M., Hajian, M., Ebrahimi-Ghiri, M. & Zarrindast, M.-R. Role of the basolateral amygdala dopamine receptors in arachidonylcyclopropylamide-induced fear learning deficits. *Psychopharmacology* **233**, 213–224 (2016).
10. Marzagalli, R. *et al.* Genetic blockade of the dopamine D3 receptor enhances hippocampal expression of PACAP and receptors and alters their cortical distribution. *Neuroscience* **316**, 279–295 (2016).
11. Li, J. J. *et al.* Fear memory recall potentiates opiate reward sensitivity through dissociable dopamine D1 versus D4 receptor-dependent memory mechanisms in the prefrontal cortex. *Journal of Neuroscience* **38**, 4543–4555 (2018).
12. Abraham, A. D., Cunningham, C. L. & Lattal, K. M. Methylphenidate enhances extinction of contextual fear. *Learning & Memory* **19**, 67–72 (2012).
13. Whittle, N. *et al.* Enhancing dopaminergic signaling and histone acetylation promotes long-term rescue of deficient fear extinction. *Translational psychiatry* **6**, e974 (2016).
14. Giustino, T. F. & Maren, S. Noradrenergic modulation of fear conditioning and extinction. *Frontiers in behavioral neuroscience* **12**, 43 (2018).
15. Bush, D. E., Caparosa, E. M., Gekker, A. & LeDoux, J. Beta-adrenergic receptors in the lateral nucleus of the amygdala contribute to the acquisition but not the consolidation of auditory fear conditioning. *Frontiers in behavioral neuroscience* **4**, 154 (2010).
16. Diaz-Mataix, L. *et al.* Characterization of the amplificatory effect of norepinephrine in the acquisition of Pavlovian threat associations. *Learning & Memory* **24**, 432–439 (2017).
17. Davies, M. F. *et al.* Activation of  $\alpha$  2 adrenergic receptors suppresses fear conditioning: expression of c-Fos and phosphorylated CREB in mouse amygdala. *Neuropsychopharmacology* **29**, 229 (2004).
18. Toth, M., Ziegler, M., Sun, P., Gresack, J. & Risbrough, V. Impaired conditioned fear response and startle reactivity in epinephrine deficient mice. *Behavioural pharmacology* **24**, 1 (2013).
19. Haaker, J. *et al.* Single dose of L-dopa makes extinction memories context-independent and prevents the return of fear. *Proceedings of the National Academy of Sciences* **110**, E2428–E2436 (2013).
20. Haaker, J., Lonsdorf, T. B. & Kalisch, R. Effects of post-extinction l-DOPA administration on the spontaneous recovery and reinstatement of fear in a human fMRI study. *European Neuropsychopharmacology* **25**, 1544–1555 (2015).
21. Gerlicher, A., Tüscher, O. & Kalisch, R. Dopamine-dependent prefrontal reactivations explain long-term benefit of fear extinction. *Nature communications* **9**, 4294 (2018).
22. Agren, T., Furmark, T., Eriksson, E. & Fredrikson, M. Human fear reconsolidation and allelic differences in serotonergic and dopaminergic genes. *Translational psychiatry* **2**, e76 (2012).
23. Lonsdorf, T. B. *et al.* Genetic gating of human fear learning and extinction: possible implications for gene-environment interaction in anxiety disorder. *Psychological science* **20**, 198–206 (2009).
24. Raczka, K. *et al.* Empirical support for an involvement of the mesostriatal dopamine system in human fear extinction. *Translational psychiatry* **1**, e12 (2011).
25. Kindt, M., Soeter, M. & Vervliet, B. Beyond extinction: erasing human fear responses and preventing the return of fear. *Nature neuroscience* **12**, 256 (2009).
26. Otis, J. M., Werner, C. T. & Mueller, D. Noradrenergic regulation of fear and drug-associated memory reconsolidation. *Neuropsychopharmacology* **40**, 793 (2015).
27. Sevenster, D., Beckers, T. & Kindt, M. Retrieval per se is not sufficient to trigger reconsolidation of human fear memory. *Neurobiology of learning and memory* **97**, 338–345 (2012).
28. Soeter, M. & Kindt, M. Stimulation of the noradrenergic system during memory formation impairs extinction learning but not the disruption of reconsolidation. *Neuropsychopharmacology* **37**, 1204 (2012).
29. Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L. & Doblin, R. The safety and efficacy of  $\pm$ 3, 4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. *Journal of Psychopharmacology* **25**, 439–452 (2011).
30. Mithoefer, M. C. *et al.* Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3, 4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. *Journal of Psychopharmacology* **27**, 28–39 (2013).
31. Jongkees, B. J., Hommel, B., Kühn, S. & Colzato, L. S. Effect of tyrosine supplementation on clinical and healthy populations under stress or cognitive demands—A review. *Journal of psychiatric research* **70**, 50–57 (2015).
32. Carmack, S. A., Howell, K. K., Rasaei, K., Reas, E. T. & Anagnostaras, S. G. Animal model of methylphenidate's long-term memory-enhancing effects. *Learning & Memory* **21**, 82–89 (2014).
33. Holtzman-Assif, O., Laurent, V. & Westbrook, R. F. Blockade of dopamine activity in the nucleus accumbens impairs learning extinction of conditioned fear. *Learning & Memory* **17**, 71–75 (2010).
34. Zbozinek, T. D., Holmes, E. A. & Craske, M. G. The effect of positive mood induction on reducing reinstatement fear: Relevance for long term outcomes of exposure therapy. *Behaviour research and therapy* **71**, 65–75 (2015).
35. Haaker, J., Lonsdorf, T. B., Thanellou, A. & Kalisch, R. Multimodal assessment of long-term memory recall and reinstatement in a combined cue and context fear conditioning and extinction paradigm in humans. *PLoS one* **8**, e76179 (2013).
36. Hermans, D. *et al.* Reinstatement of fear responses in human aversive conditioning. *Behaviour research and therapy* **43**, 533–551 (2005).
37. Ho, Y. & Lipp, O. V. Faster acquisition of conditioned fear to fear-relevant than to nonfear-relevant conditional stimuli. *Psychophysiology* **51**, 810–813 (2014).
38. Luck, C. C. *et al.* Temporal context cues in human fear conditioning: Unreinforced conditional stimuli can segment learning into distinct temporal contexts and drive fear responding. *Behaviour research and therapy* **108**, 10–17 (2018).
39. Merz, C. J., Hamacher-Dang, T. C. & Wolf, O. T. Exposure to stress attenuates fear retrieval in healthy men. *Psychoneuroendocrinology* **41**, 89–96 (2014).
40. McNally, G. P., Johansen, J. P. & Blair, H. T. Placing prediction into the fear circuit. *Trends in neurosciences* **34**, 283–292 (2011).
41. Rescorla, R. A. & Wagner, A. R. A theory of Pavlovian conditioning: Variations in the effectiveness of reinforcement and nonreinforcement. *Classical conditioning II: Current research and theory* **2**, 64–99 (1972).
42. Sutton, R. S. & Barto, A. G. Toward a modern theory of adaptive networks: expectation and prediction. *Psychological review* **88**, 135 (1981).
43. Schultz, W. & Dickinson, A. Neuronal coding of prediction errors. *Annual review of neuroscience* **23**, 473–500 (2000).



44. Waelti, P., Dickinson, A. & Schultz, W. Dopamine responses comply with basic assumptions of formal learning theory. *Nature* **412**, 43 (2001).
45. Brischoux, F., Chakraborty, S., Brierley, D. I. & Ungless, M. A. Phasic excitation of dopamine neurons in ventral VTA by noxious stimuli. *Proceedings of the national academy of sciences* **106**, 4894–4899 (2009).
46. Groessl, F. *et al.* Dorsal tegmental dopamine neurons gate associative learning of fear. *Nature neuroscience* **1** (2018).
47. Matsumoto, M. & Hikosaka, O. Two types of dopamine neuron distinctly convey positive and negative motivational signals. *Nature* **459**, 837 (2009).
48. Atlas, L. Y., Doll, B. B., Li, J., Daw, N. D. & Phelps, E. A. Instructed knowledge shapes feedback-driven aversive learning in striatum and orbitofrontal cortex, but not the amygdala. *Elife* **5**, e15192 (2016).
49. Onur, O. A. *et al.* Noradrenergic enhancement of amygdala responses to fear. *Social cognitive and affective neuroscience* **4**, 119–126 (2009).
50. Visser, R. M., Kunze, A. E., Westhoff, B., Scholte, H. S. & Kindt, M. Representational similarity analysis offers a preview of the noradrenergic modulation of long-term fear memory at the time of encoding. *Psychoneuroendocrinology* **55**, 8–20 (2015).
51. Cools, R. & D'Esposito, M. Inverted-U-shaped dopamine actions on human working memory and cognitive control. *Biological psychiatry* **69**, e113–e125 (2011).
52. Lachman, H. M. *et al.* Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. *Pharmacogenetics* **6**, 243–250 (1996).
53. Foster, H. D. & Hoffer, A. The two faces of L-DOPA: benefits and adverse side effects in the treatment of Encephalitis lethargica, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis. *Medical Hypotheses* **62**, 177–181 (2004).
54. Duits, P. *et al.* Updated meta-analysis of classical fear conditioning in the anxiety disorders. *Depression and anxiety* **32**, 239–253 (2015).
55. Lissek, S. *et al.* Classical fear conditioning in the anxiety disorders: a meta-analysis. *Behaviour research and therapy* **43**, 1391–1424 (2005).
56. Davis, M., Falls, W. A. & Gewirtz, J. In *Contemporary issues in modeling psychopathology* 113–141 (Springer, 2000).
57. Hardman, C. A., Herbert, V. M., Brunstrom, J. M., Munafo, M. R. & Rogers, P. J. Dopamine and food reward: effects of acute tyrosine/phenylalanine depletion on appetite. *Physiology & behavior* **105**, 1202–1207 (2012).
58. Colzato, L., Jongkees, B., Sellaro, R. & Hommel, B. Working memory reloaded: tyrosine repletes updating in the N-back task. *Frontiers in behavioral neuroscience* **7**, 200 (2013).
59. Colzato, L. S., Jongkees, B. J., Sellaro, R., van den Wildenberg, W. P. M. & Hommel, B. Eating to stop: Tyrosine supplementation enhances inhibitory control but not response execution. *Neuropsychologia* **62**, 398–402, <https://doi.org/10.1016/j.neuropsychologia.2013.12.027> (2014).
60. Brodnik, Z., Bongiovanni, R., Double, M. & Jaskiw, G. E. Increased tyrosine availability increases brain regional DOPA levels *in vivo*. *Neurochemistry international* **61**, 1001–1006 (2012).
61. Glaeser, B. S., Melamed, E., Growdon, J. H. & Wurtman, R. J. Elevation of plasma tyrosine after a single oral dose of L-tyrosine. *Life sciences* **25**, 265–271 (1979).
62. Tam, S.-Y., Elsworth, J., Bradberry, C. & Roth, R. Mesocortical dopamine neurons: high basal firing frequency predicts tyrosine dependence of dopamine synthesis. *Journal of Neural Transmission/General Section JNT* **81**, 97–110 (1990).
63. Morris, J., Christakou, A. & Van Reekum, C. M. Nothing is safe: Intolerance of uncertainty is associated with compromised fear extinction learning. *Biological psychology* **121**, 187–193 (2016).
64. Asthana, M. K. *et al.* Preventing the return of fear using reconsolidation update mechanisms depends on the met-allele of the brain derived neurotrophic factor Val66Met polymorphism. *International Journal of Neuropsychopharmacology* **19** (2016).
65. Mathôt, S., Schreij, D. & Theeuwes, J. OpenSesame: An open-source, graphical experiment builder for the social sciences. *Behavior research methods* **44**, 314–324 (2012).
66. Mueller, S. T. & Piper, B. J. The psychology experiment building language (PEBL) and PEBL test battery. *Journal of neuroscience methods* **222**, 250–259 (2014).
67. Riby, L. M. *et al.* Impulsiveness, postprandial blood glucose, and glucoregulation affect measures of behavioral flexibility. *Nutrition Research* **48**, 65–75 (2017).
68. Teik, D. O. L. *et al.* Ginseng and ginkgo biloba effects on cognition as modulated by cardiovascular reactivity: a randomised trial. *PloS one* **11**, e0150447 (2016).
69. Dennison, O., Gao, J., Lim, L. W., Stagg, C. J. & Aquili, L. Catecholaminergic modulation of indices of cognitive flexibility: A pharmac-tDCS study. *Brain stimulation* **12**, 290–295 (2019).
70. Fernstrom, J. D. Aromatic amino acids and monoamine synthesis in the central nervous system: influence of the diet. *The Journal of Nutritional Biochemistry* **1**, 508–517, [https://doi.org/10.1016/0955-2863\(90\)90033-H](https://doi.org/10.1016/0955-2863(90)90033-H) (1990).
71. Cacciaglia, R. *et al.* A risk variant for alcoholism in the NMDA receptor affects amygdala activity during fear conditioning in humans. *Biological Psychology* **94**, 74–81, <https://doi.org/10.1016/j.biopsycho.2013.05.006> (2013).

## Acknowledgements

We would like to thank Joseph Bretten, Ellie Holah, Lucy Longstaff, Michael Mcniffe, Adam Northall, Lorna Wooldridge for helping out to collect the data. We would like to thank Martin Thirkettle for helpful comments on the manuscript.

## Author contributions

A.S. performed the statistical analysis of the data; wrote the manuscript; L.A. designed the experiments, performed the statistical analysis of the data, and wrote the manuscript.

## Competing interests

The authors declare no competing interests.

## Additional information

**Supplementary information** is available for this paper at <https://doi.org/10.1038/s41598-019-52610-x>.

**Correspondence** and requests for materials should be addressed to L.A.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019